6505--Allopurinol Tablets Effective May 30, 2026 to May 29, 2027

Solicitation / RFP / RFQ

This document is a solicitation for Allopurinol Tablets, with a period of performance effective from May 30, 2026, to May 29, 2027. The contracting office is the Department of Veterans Affairs, National Acquisition Center, located in Hines, IL.

• Procurement of Allopurinol Tablets.

• Product Service Code: 6505

• NAICS Code: 325412 (Pharmaceutical and Medicine Manufacturing)

• Award Number: 36E79726D0024

• Award Amount: $17,786,862.00

• Award Date: March 9, 2026

• Awardee: XLCARE PHARMACEUTICALS INC

• Contractor UEI: MEAUS5WHBJJ7

• Awardee Address: 242 S CULVER ST, LAWRENCEVILLE, GA 30046

Not explicitly detailed in the provided text, as this appears to be award information rather than a pre-award solicitation document.

Not specified in the provided text.

This document primarily contains award information for the Allopurinol Tablets contract. The solicitation number associated with this award is 36E79725R0067.

Amendment / Modification

This amendment extends the closing date for Solicitation 36E79725R0067.

• The hour and date for the receipt of offers is extended.

• The closing date for receipt of offers is extended from 11/24/2025 to 12/02/2025 at 2:30 PM Central Time (CT).

• All other solicitation terms and conditions remain unchanged.

Solicitation / RFP / RFQ

This solicitation seeks proposals for the supply of Allopurinol tablets (100mg and 300mg) in various package sizes (100, 500, and 1000 tablets per bottle). The contract will serve as a supply source for the VA and Department of Defense (DoD) Pharmaceutical Prime Vendor (PPV) Programs, aiming to ensure nationwide availability and obtain volume-based pricing.

• Products: Allopurinol 100mg and 300mg tablets in specified bottle counts.

• Packaging: Must meet specific requirements including safety caps for bottles of 400 tablets or less, compatibility with automated dispensing units, and no glass bottles.

• Labeling: Must include an 11-digit National Drug Code (NDC) unique to the offeror.

• Barcoding: Pharmaceutical products require GS1-128 or HIBCC compliant bar code labeling at the unit-of-use package level.

• DSCSA Compliance: Adherence to Drug Supply Chain Security Act requirements, including serialized transaction information and statements.

• Manufacturing: Facilities must have acceptable cGMP status with the FDA. Offerors must identify manufacturing locations and provide FDA clearance details.

• Cost Recovery Fee: A 0.5% Cost Recovery Fee must be included in all offered prices.

• Contract Type: Firm Fixed Price, Indefinite-Delivery Requirements contract.

• Period of Performance: Base ordering period of one year, with four one-year option periods. A 60-day implementation period is also included.

• Award: One award will be made in the aggregate for all line items.

• Submission Method: Proposals must be submitted via email in Microsoft Word or PDF format to Matthew.Poulin@va.gov and Nicholas.McGregor@va.gov. A scanned PDF of the signed SF-1449 is required. Faxed proposals are not acceptable.

• Proposal Content: Must include pricing for the base year and all four option years for all line items, NDC numbers, and meet packaging requirements.

• Evaluation: Award will be made to the lowest price technically acceptable offer. Technical acceptability includes meeting product descriptions, NDC uniqueness, FDA approval, FDA cGMP compliance, and manufacturing facility clearance.

• Deadline: Offer Due Date is November 24, 2025, at 2:30 PM CT.

• NAICS Code: 325412 (Pharmaceutical Preparation Manufacturing).

• Size Standard: 1300 Employees.

• Small Business: Offerors must comply with subcontracting plan requirements if applicable (contracts over $750,000).

• Manufacturer Requirements: If not the manufacturer, a Letter of Commitment from the manufacturer is required.

• Offerors must submit pricing for all line items and option years to be considered.

• Prices must not exceed two decimal places.

• NDC numbers must be unique to the offeror and specific to the drug offered.

• Attachments A and B list the VA and DoD Pharmaceutical Prime Vendors.